These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34330955)

  • 1. Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure.
    Cornelissen A; Florescu R; Kneizeh K; Cornelissen C; Brandenburg V; Liehn E; Schuh A
    Sci Rep; 2021 Jul; 11(1):15507. PubMed ID: 34330955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
    Ter Maaten JM; Voors AA; Damman K; van der Meer P; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Navis G; Ng L; Ouwerkerk W; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; de Borst MH
    Int J Cardiol; 2018 Feb; 253():84-90. PubMed ID: 29306478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23 in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Lyngbakken MN; Pervez MO; Brynildsen J; Pedersen MH; Sølvernes J; Christensen G; Høiseth AD; Omland T; Røsjø H
    Clin Biochem; 2018 Feb; 52():41-47. PubMed ID: 29074091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of fibroblast growth factor 23 for predicting acute kidney injury in patients with acute decompensated heart failure.
    Pramong N; Gojaseni P; Suttipongkeat S; Kiattisunthorn K; Chittinandana A
    Nephrology (Carlton); 2021 Feb; 26(2):126-133. PubMed ID: 32902010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intact and C-Terminal FGF23 Assays-Do Kidney Function, Inflammation, and Low Iron Influence Relationships With Outcomes?
    Sharma S; Katz R; Bullen AL; Chaves PHM; de Leeuw PW; Kroon AA; Houben AJHM; Shlipak MG; Ix JH
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4875-85. PubMed ID: 32951052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure.
    Isakova T; Houston J; Santacruz L; Schiavenato E; Somarriba G; Harmon WG; Lipshultz SE; Miller TL; Rusconi PG
    Pediatr Nephrol; 2013 Oct; 28(10):2035-42. PubMed ID: 23740037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial.
    Stöhr R; Brandenburg VM; Heine GH; Maeder MT; Leibundgut G; Schuh A; Jeker U; Pfisterer M; Sanders-van Wijk S; Brunner-la Rocca HP
    Eur J Heart Fail; 2020 Apr; 22(4):701-709. PubMed ID: 32020782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study.
    Chua W; Law JP; Cardoso VR; Purmah Y; Neculau G; Jawad-Ul-Qamar M; Russell K; Turner A; Tull SP; Nehaj F; Brady P; Kastner P; Ziegler A; Gkoutos GV; Pavlovic D; Ferro CJ; Kirchhof P; Fabritz L
    PLoS Med; 2021 Feb; 18(2):e1003405. PubMed ID: 33534825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.
    Edmonston D; Wojdyla D; Mehta R; Cai X; Lora C; Cohen D; Townsend RR; He J; Go AS; Kusek J; Weir MR; Isakova T; Pencina M; Wolf M;
    Am J Kidney Dis; 2019 Dec; 74(6):771-781. PubMed ID: 31445926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma total fibroblast growth factor 23 levels are associated with acute kidney injury and mortality in children with acute respiratory distress syndrome.
    Hanudel MR; Zinter MS; Chen L; Gala K; Lim M; Guglielmo M; Deshmukh T; Vangala S; Matthay M; Sapru A
    PLoS One; 2019; 14(9):e0222065. PubMed ID: 31487315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast Growth Factor 23 and Outcome Prediction in Patients with Acute Myocardial Infarction.
    Cornelissen A; Florescu R; Kneizeh K; Cornelissen C; Liehn E; Brandenburg V; Schuh A
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease.
    Imazu M; Takahama H; Asanuma H; Funada A; Sugano Y; Ohara T; Hasegawa T; Asakura M; Kanzaki H; Anzai T; Kitakaze M
    Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1504-11. PubMed ID: 25217649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure.
    Andersen IA; Huntley BK; Sandberg SS; Heublein DM; Burnett JC
    Nephrol Dial Transplant; 2016 May; 31(5):767-72. PubMed ID: 26666498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of mortality and need for renal replacement therapy in patients of acute kidney injury using fibroblast growth factor 23.
    Fayed A; Radwan WA; Amin M; Gamal A
    Saudi J Kidney Dis Transpl; 2019; 30(5):1044-1051. PubMed ID: 31696842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
    de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor 23 and Long-Term Cardiac Function: The Multi-Ethnic Study of Atherosclerosis.
    Patel RB; Ning H; de Boer IH; Kestenbaum B; Lima JAC; Mehta R; Allen NB; Shah SJ; Lloyd-Jones DM
    Circ Cardiovasc Imaging; 2020 Nov; 13(11):e011925. PubMed ID: 33161733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.